Related Experiment Video
Updated: Sep 3, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Metabolic Adaptation-Mediated Cancer Survival and Progression in Oxidative Stress
Yongquan Tang1,2, Zhe Zhang2, Yan Chen2
1Department of Pediatric Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Abstract:
Undue elevation of ROS levels commonly occurs during cancer evolution as a result of various antitumor therapeutics and/or endogenous immune response. Overwhelming ROS levels induced cancer cell death through the dysregulation of ROS-sensitive glycolytic enzymes, leading to the catastrophic depression of glycolysis and oxidative phosphorylation (OXPHOS), which are critical for cancer survival and progression. However, cancer cells also adapt to such catastrophic oxidative and metabolic stresses by metabolic reprograming, resulting in cancer residuality, progression, and relapse. This adaptation is highly dependent on NADPH and GSH syntheses for ROS scavenging and the upregulation of lipolysis and glutaminolysis, which fuel tricarboxylic acid cycle-coupled OXPHOS and biosynthesis. The underlying mechanism remains poorly understood, thus presenting a promising field with opportunities to manipulate metabolic adaptations for cancer prevention and therapy. In this review, we provide a summary of the mechanisms of metabolic regulation in the adaptation of cancer cells to oxidative stress and the current understanding of its regulatory role in cancer survival and progression.
Insights
Cancer cells adapt to oxidative stress via metabolic reprogramming, utilizing NADPH and GSH for ROS scavenging. Understanding these adaptations is key for developing new cancer therapies.
Area of Science:
- Oncology
- Metabolic pathways
- Cellular stress response
Background:
- Elevated reactive oxygen species (ROS) levels are common in cancer evolution, driven by therapies and immune responses.
- High ROS can induce cancer cell death by disrupting glycolysis and oxidative phosphorylation (OXPHOS).
- Cancer cells exhibit metabolic reprogramming to survive oxidative and metabolic stress, leading to residual disease and relapse.
Purpose of the Study:
- To summarize mechanisms of metabolic regulation in cancer cell adaptation to oxidative stress.
- To review the role of metabolic adaptations in cancer survival and progression.
- To highlight opportunities for therapeutic intervention by manipulating cancer cell metabolism.
Main Methods:
- Literature review of studies on cancer cell metabolism and oxidative stress.
- Analysis of metabolic reprogramming strategies employed by cancer cells.
- Synthesis of current understanding of ROS-scavenging pathways (NADPH, GSH) and metabolic shifts (lipolysis, glutaminolysis).
Main Results:
- Cancer cells adapt to ROS-induced metabolic disruption through reprogramming.
- Key adaptations include NADPH and GSH synthesis for ROS scavenging.
- Upregulation of lipolysis and glutaminolysis supports OXPHOS and biosynthesis, fueling cancer progression.
Conclusions:
- Metabolic reprogramming is crucial for cancer cell survival under oxidative stress.
- Understanding these adaptive mechanisms offers therapeutic targets for cancer prevention and treatment.
- Further research into the underlying mechanisms can guide novel anti-cancer strategies.
More Related Videos
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Survival Analysis
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
PI3K/mTOR/AKT Signaling Pathway

